Clinical trial
A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
NCT00336310 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
- Lead sponsor
- National Cheng-Kung University Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- July 31, 2006
- Completion date
- Not reported
- Enrollment
- 50
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.